Cells (Mar 2023)

Recent Emerging Immunological Treatments for Primary Brain Tumors: Focus on Chemokine-Targeting Immunotherapies

  • Alessio Ardizzone,
  • Rossella Basilotta,
  • Alessia Filippone,
  • Lelio Crupi,
  • Marika Lanza,
  • Sofia Paola Lombardo,
  • Cristina Colarossi,
  • Dorotea Sciacca,
  • Salvatore Cuzzocrea,
  • Emanuela Esposito,
  • Michela Campolo

DOI
https://doi.org/10.3390/cells12060841
Journal volume & issue
Vol. 12, no. 6
p. 841

Abstract

Read online

Primary brain tumors are a leading cause of death worldwide and are characterized by extraordinary heterogeneity and high invasiveness. Current drug and radiotherapy therapies combined with surgical approaches tend to increase the five-year survival of affected patients, however, the overall mortality rate remains high, thus constituting a clinical challenge for which the discovery of new therapeutic strategies is needed. In this field, novel immunotherapy approaches, aimed at overcoming the complex immunosuppressive microenvironment, could represent a new method of treatment for central nervous system (CNS) tumors. Chemokines especially are a well-defined group of proteins that were so named due to their chemotactic properties of binding their receptors. Chemokines regulate the recruitment and/or tissue retention of immune cells as well as the mobilization of tumor cells that have undergone epithelial–mesenchymal transition, promoting tumor growth. On this basis, this review focuses on the function and involvement of chemokines and their receptors in primary brain tumors, specifically examining chemokine-targeting immunotherapies as one of the most promising strategies in neuro-oncology.

Keywords